These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 34721394)
1. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells. Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N Front Immunol; 2021; 12():730342. PubMed ID: 34721394 [TBL] [Abstract][Full Text] [Related]
2. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571 [TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for multiple sclerosis. He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123 [TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for multiple sclerosis. He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397 [TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report. Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096 [TBL] [Abstract][Full Text] [Related]
7. Teriflunomide and its mechanism of action in multiple sclerosis. Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824 [TBL] [Abstract][Full Text] [Related]
8. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956 [No Abstract] [Full Text] [Related]
9. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. Comi G; Miller AE; Benamor M; Truffinet P; Poole EM; Freedman MS Mult Scler; 2020 Aug; 26(9):1083-1092. PubMed ID: 31172849 [TBL] [Abstract][Full Text] [Related]
10. An updated review of teriflunomide's use in multiple sclerosis. Miller AE Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382 [TBL] [Abstract][Full Text] [Related]
11. Teriflunomide, a potential novel cause of chronic active colitis. Kővári B; Zachs J; Murchie B; Lauwers GY Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888 [No Abstract] [Full Text] [Related]
12. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases. Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325 [TBL] [Abstract][Full Text] [Related]
13. Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Khurana D; Kaur G; Sendhil Kumaran M; Choudhary R; Ashraf R; Thakur V Clin Exp Dermatol; 2021 Jan; 46(1):166-169. PubMed ID: 32557734 [No Abstract] [Full Text] [Related]
14. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862 [TBL] [Abstract][Full Text] [Related]
15. Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study. Lycke J; Farman H; Nordin A CNS Drugs; 2023 Feb; 37(2):181-188. PubMed ID: 36729276 [TBL] [Abstract][Full Text] [Related]
16. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Medina S; Sainz de la Maza S; Villarrubia N; Álvarez-Lafuente R; Costa-Frossard L; Arroyo R; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM Ann Clin Transl Neurol; 2019 Feb; 6(2):355-363. PubMed ID: 30847367 [TBL] [Abstract][Full Text] [Related]
17. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Papadopoulou A; Kappos L; Sprenger T Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study. Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149 [No Abstract] [Full Text] [Related]
19. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis. Scott LJ Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896 [TBL] [Abstract][Full Text] [Related]
20. Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis. Wu Q; Wang Q; Yang J; Mills EA; Chilukuri P; Saad A; Dowling CA; Fisher C; Kirch B; Mao-Draayer Y Mult Scler Relat Disord; 2023 Jul; 75():104719. PubMed ID: 37172367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]